Mays Cancer Center researcher and SignalRx earn NCI business grants to develop drugs for first-in-human clinical trials
March 10, 2022
Contact: Steven Lee, 210-450-3823, lees22@uthscsa.edu SAN ANTONIO – An internationally recognized physician-scientist of Mays Cancer Center at UT Health San Antonio together with SignalRx Pharmaceuticals Inc. have secured two National Cancer Institute business grants to further develop drugs on a pathway to first-in-human cancer clinical trials. The clinical translational researcher, Daruka Mahadevan, MD, PhD, division […]